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Interleukin-10 is a pleiotropic cytokine known to
have inhibitory effects on the accessory functions of
dendritic cells. In vitro, interleukin-10 converts imma-
ture dendritic cells into tolerizing antigen-
presenting cells. To assess whether interleukin-10-
treated dendritic cells exert tolerizing effects in vivo,
CD4+ T cells from DO11.10 ovalbumin±T cell recep-
tor transgenic mice were transferred to syngeneic
BALB/c recipients. Recipient animals were treated
with ovalbumin-pulsed/unpulsed, interleukin-10-
treated/untreated CD11c+ dendritic cells thereafter
and ovalbumin-speci®c proliferation of lymph node
cells was assessed by restimulation with the peptide
in vitro. In prophylactic experiments, recipients
received naive CD4+ DO11.10 T cells and were
immunized with ovalbumin323±339 peptide in incom-
plete Freund's adjuvant after treatment with various
subtypes of dendritic cells. Strong ovalbumin-speci®c
proliferation was observed in animals immunized
with control ovalbumin-dendritic cells. Minimal pro-
liferation was found in mice treated with ovalbumin-
pulsed, interleukin-10-treated dendritic cells. In
therapeutic experiments, preactivated CD4+ DO11.10
T cells were transferred, and recipients were treated
with dendritic cells as described. Ovalbumin-speci®c
proliferation was strong in recipients treated with
ovalbumin-dendritic cells. CD4+ T cell proliferation
from ovalbumin±interleukin-10±dendritic cell treated
animals was below background. When delayed type
hypersensitivity reactions in the footpads of pro-
phylactically or therapeutically vaccinated animals
were tested, mice treated with ovalbumin±inter-
leukin-10±dendritic cells showed no footpad swelling
compared with controls. Rechallenge with the anti-
gen in vitro and in vivo did not alter the inhibitory
effect of interleukin-10-treated dendritic cells. Thus,
interleukin-10-treated dendritic cells inhibit ovalbu-
min-speci®c immune responses in naive and sensi-
tized mice. Key words: dendritic cells/interleukin-10/
ovalbumin. J Invest Dermatol 119:836±841, 2002
D
endritic cells (DC) are potent immunostimulatory
cells whose capabilities to process and present
antigen are unmatched in the immune system
(Banchereau and Steinman, 1998). Besides serving
as potent immunostimulatory cells, DC can be
converted to tolerance-inducing cells under certain conditions
(Schuler and Steinman, 1985; Steinman and Young, 1991; Young
et al, 1992). One of the factors known to affect DC in such a way
that they become tolerizing antigen-presenting cells (APC) is
interleukin-10 (IL-10) (de Waal et al, 1992a). It was shown by us
and others previously that IL-10 is able to affect the expression of
major histocompatibility complex (MHC) and costimulatory
molecules such as CD86 on DC (Steinbrink et al, 1997).
Although the original work was performed in murine Langerhans
cells (Enk et al, 1993; 1997; Dummer et al, 1995; 1996), similar
results were obtained in various subtypes of murine and human
DC. As an example, IL-10-treated human-blood-derived DC
induced anergy in CD4+ and CD8+ clonal or naive T cells.
Induction of anergy in melanoma-antigen-speci®c T cell lines also
resulted in a failure of these cytotoxic T lymphocytes to lyze tumor
cells (Pisa et al, 1992; Gastl et al, 1993; Merlo et al, 1993; Smith et al,
1994; Kim et al, 1995; Steinbrink et al, 1999). Additionally, data
generated in patients with malignant melanoma showed that
progressing metastases in contrast to regressing metastases contained
high amounts of IL-10 (Enk et al, 1997). This IL-10 was derived
from melanoma cells and inhibited the expression of CD86 on local
DC. Therefore these DC were not only inhibited with regard to
their potency to induce T cell proliferation, but also induced
tolerance in the patients' T cells. In aggregate these data indicate
that IL-10 serves as a factor that alters DC functions in such a way
that these DC induce T cell tolerance. As tolerance induction
might be a useful way to treat murine or human autoimmune
diseases, we wondered whether IL-10-treated DC (DC-IL10)
might also subserve tolerizing functions in vivo.
To address the question of downregulation of immune responses
by DC in vivo, we used a system of ovalbumin (OVA)±T cell
receptor (TCR) transgenic animals (DO11.10 mice) where 50%±
70% of all naive peripheral CD4+ T cells express an OVA-speci®c
TCR (Murphy et al, 1990). This system provides the advantage that
a large number of peptide-speci®c T cells can be readily stimulated
with the appropriate antigen. To exclude an in¯uence of newly
developing transgenic T cells that were not affected by the DC
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injected and to test transgenic T cells in a ``normal'' nontransgenic
environment, CD4+ T cells from transgenic animals were trans-
ferred ex vivo into syngeneic BALB/c mice (Kearney et al, 1994).
We demonstrate that pretreatment of DC with IL-10 alters the
APC functions of these cells in such a way that DC-IL10 are able to
prevent and downmodulate activation of transgenic CD4+ T cells
in vivo. Therefore, DC-IL10 might provide a potent tool for the
prevention and treatment of murine or human autoimmune
diseases.
MATERIALS AND METHODS
Animals BALB/c mice (H-2d) and OVA-TCR DO11.10 mice
(kindly provided by Dr. Dennis Loh, H-2d, OVA323±339 peptide) were
bred in the animal facility of the Institute of Immunology in Mainz and
used at 8±12 wk of age. For in vivo experiments ®ve mice were used in
each group (Murphy et al, 1990).
Culture medium for DC RPMI 1640 was supplemented with 100 IU
per ml penicillin, 100 mg per ml streptomycin, 5 3 10±5 M 2¢-
mercaptoethanol, 2 mM glutamine, 10 mM HEPES, and 1.5% heat-
inactivated pooled BALB/c mouse serum. All cytokines used were
recombinant mouse proteins. Final concentrations used in the cultures
were 10 ng per ml for granulocyte±macrophage colony-stimulating factor
(GM-CSF), 10 ng per ml for IL-4, and 30 ng per ml IL-10 (Schering-
Plough).
Antibodies and magnetic beads The following antibodies were used
anti-CD4 (clone GK1.5, ATCC, Rockville, MD), rIgG2b, RB6-8C5
(clone Ly-6G/Gr-1, ATCC), rIgG2a, class II I-A
b,d,q, I-Ed,k (clone M5/
114.15.2, ATCC), rIgG2b, anti-CD80 (clone 16-10A1, PharMingen),
anti-CD86 (clone GL1, PharMingen), anti-CD62L (clone MEL14,
PharMingen).
For magnetic separation we used the following beads: CD4-micro-
beads (Miltenyi Biotec, Bergisch-Gladbach, Germany).
Generation of fetal-bovine-serum-free bone-marrow-derived DC
(BM-DC) Murine BM-DC were grown according to published
protocols in RPMI medium supplemented with 10 ng per ml
recombinant murine GM-CSF (rmGM-CSF), 10 ng per ml recombinant
murine IL-4 (rmIL-4), and 1.5% mouse serum in a ®nal volume of
25 ml. At day 2 cells were treated with 30 mg per ml rmIL-10 or left
untreated. On day 5 of culture, nonadherent cells were pulsed with
50 mg per ml OVA or left unpulsed. After 2 d cells were assessed by
¯uorescence-activated cell sorter (FACS) for expression of CD11c, MHC
class II, and costimulatory molecules (CD80, CD86). Regular yields
were > 70% CD11c+ DC.
Generation of epidermal cells Mice were sacri®ced and ears
removed. After disinfection with 70% ethanol ears were split into dorsal
and ventral halves using ®ne tweezers. Subcutaneous fat and cartilage
were removed by scraping with the tweezers. Ear halves were digested in
0.5% trypsin/0.2 mM ethylenediamine tetraacetic acid for 30 min. The
epidermis was removed easily and epidermal cells were washed out of
the tissue. After incubation of the cells in RPMI medium supplemented
with 100 IU per ml penicillin, 100 mg per ml streptomycin, 5 3 10±5 M
2¢-mercaptoethanol, 2 mM glutamine, 10% fetal bovine serum, and
30 mg per ml OVA overnight Langerhans cells were enriched by density
centrifugation.
Prevention of OVA-speci®c immune responses in vivo
(Fig 1A) CD4+ T cells of naive DO11.10 mice were puri®ed with
magnetic beads (Miltenyi, 98% purity) and injected intravenously into
naive BALB/c mice (5 3 106 cells per mouse). Mice were injected
intravenously with 5 3 105 DC treated with IL-10 or left untreated and
pulsed with OVA or left unpulsed 48 h later. After a rest period of 8 d
mice were sensitized by subcutaneous injection with 30 mg OVA323±339
peptide in incomplete Freund's adjuvant (IFA). Ten days later mice were
either sacri®ced to obtain lymph node cells for in vitro analysis or injected
into the footpad with 30 mg OVA323±339 peptide in IFA for analysis of
delayed-type hypersensitivity (DTH) reactions in vivo. The ratio of
OVA-TCR transgenic CD4+ T cells contained in lymph node cells was
analyzed by FACS and equal amounts were used for restimulation.
Proliferation of OVA-speci®c T cells restimulated with 5 mg per ml
OVA323±339 peptide was measured by 3H-thymidine incorporation. As
tolerance control mice were injected once with 300 mg OVA323±339
peptide intraperitoneally and lymph node cells were processed as
described.
Inhibition of an existing OVA-speci®c immune response in vivo
(Fig 1B) DO11.10 mice were sensitized three times every other day
with 5 mg OVA per mouse subcutaneously in IFA. CD4+ T cells of
these sensitized DO11.10 mice were isolated from lymph node cells
(98% purity) and injected intravenously into naive BALB/c mice
(5 3 106 cells per mouse). Mice were injected intravenously with
5 3 105 DC treated with IL-10 or left untreated and pulsed with OVA
or left unpulsed 48 h later. After a rest period of 8 d mice were either
sacri®ced to obtain lymph node cells for in vitro analysis or injected into
the footpad with 30 mg OVA323±339 peptide in IFA for analysis of DTH
reactions in vivo. The ratio of OVA-TCR transgenic CD4+ T cells
contained in lymph node cells was analyzed by FACS and equal amounts
were used for restimulation. Proliferation of OVA-speci®c T cells
restimulated with 5 mg per ml OVA323±339 peptide was measured by 3H-
thymidine incorporation.
Antigen restimulation in vivo and in vitro For ex vivo restimulation
analysis lymph node and spleen cells were prepared from all animals
injected with DO11.10 cells and DC. CD4+ T cells were isolated and
stimulated with OVA-pulsed epidermal cells. Three days later the
medium was supplemented with 2 U per ml rhIL-2. After 10 d CD4+
cells were harvested and equal numbers of OVA-speci®c T cells were
restimulated with OVA-pulsed epidermal cells. Proliferation was
measured by 3H-thymidine incorporation.
For in vivo restimulation mice reconstituted with CD4+ DO11.10 T
cells and injected with DC as described were restimulated by subcuta-
neuos injection with 30 mg OVA323±339 peptide in IFA. Ten days later
mice were injected into the footpad with 30 mg OVA323±339 peptide in
IFA or IFA alone into the contralateral footpad for analysis of DTH
reactions.
RESULTS
IL-10-treated DC inhibit immune responses of naive T cells
in vivo CD4+ T cells from naive DO11.10 mice were injected
into syngeneic BALB/c mice. Two days later, animals transplanted
Figure 1. Experimental systems. (A) CD4+ T cells of naive
DO11.10 mice were puri®ed and injected intravenously into naive
BALB/c mice (5 3 106 cells per mouse). Mice were injected
intravenously with 5 3 105 DC 48 h later. After a rest period of 8 d
mice were sensitized by subcutaneuos injection with 30 mg OVA323±339
peptide in IFA. Ten days later mice were either sacri®ced to obtain
lymph node cells for in vitro analysis or injected into the footpad with
30 mg OVA323±339 peptide in IFA for analysis of DTH reactions in vivo.
(B) CD4+ T cells of presensitized DO11.10 mice were injected
intravenously into naive BALB/c mice (5 3 106 cells per mouse). Mice
were injected intravenously with 5 3 105 DC 48 h later. After a rest
period of 8 d mice were either sacri®ced to obtain lymph node cells for
in vitro analysis or injected into the footpad with 30 mg OVA323±339
peptide in IFA for analysis of DTH reactions in vivo. To analyze whether
the effects seen were long lasting, some mice were rechallenged with
antigen at day 10 (A) or day 20 (B) and DTH experiments and in vitro
analysis were performed 10 d later.
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with transgenic T cells were injected intravenously with 5 3 105
BM-DC from normal BALB/c mice that were either pulsed with
OVA (DC-OVA) or pulsed with OVA and pretreated with IL-10
(DC-OVA-IL10). Control mice received DC that were pretreated
with IL-10 (DC-IL10) or left untreated (DC). Prior to injection
DC were analyzed by FACS staining. IL-10 treatment reduced the
expression of both stimulatory (MHC II) and costimulatory
molecules (CD80, CD86, CD40). Expression of the DC marker
CD11c was not affected (data not shown). After a period of 8 d
animals were stimulated with the immunogenic OVA323±339
peptide by subcutaneous injection. Ten days later, total lymph
node cells (containing APC) from these animals were prepared and
restimulated with the peptide in vitro. The number of OVA-TCR
transgenic T cells was determined by FACS and equal amounts
were used for restimulation. Proliferation was measured after 3 d by
thymidine incorporation. Whereas lymph node cells from mice
treated with OVA-pulsed DC (DC-OVA) in vivo proliferated well
to antigenic restimulation in vitro, there was only limited
proliferation in the lymph node cells derived from animals treated
with IL-10-treated OVA-pulsed DC (DC-OVA-IL10). This result
is in concordance with the effects of DC-OVA-IL10 seen after
stimulation in vitro (data not shown). The amount of proliferation
detectable in this group was comparable to the amount of
proliferation visible in the tolerance control group (lymph node
cells from animals tolerized by intraperitoneal injection of
immunogenic peptide in IFA) (Fig 2). Omission of antigen in
the in vivo treatment resulted in proliferation rates similar to that
observed with lymph node cells from naive animals. To analyze
whether the inhibitory effects seen remained after antigen
restimulation, CD4+ T cells were isolated from mice injected
with DC-OVA and DC-OVA-IL10, respectively, and were
restimulated with OVA-pulsed epidermal cells. After 3 d the
medium was supplemented with 2 U per ml IL-2. After a rest
period equal numbers of OVA-TCR transgenic T cells were
restimulated with OVA-pulsed epidermal cells. CD4+ T cells from
mice injected with DC-OVA-IL10 after reconstitution with naive
CD4+ DO11.10 T cells remained impaired in their capacity to
proliferate (Fig 3). CD4+ T cells isolated from mice injected with
DC or DC-IL10 were driven into cell death by ex vivo
restimulation.
These data indicate that IL-10-treated DC inhibit antigen-
speci®c immune responses in naive CD4+ transgenic T cells in vivo.
This inhibition persists after multiple rounds of restimulation.
IL-10-treated DC are able to suppress preexisting immune
responses in transgenic T cells in vivo DO11.10 mice were
sensitized by subcutaneous injection of OVA in IFA. CD4+ T cells
from these animals were prepared as described and injected
intravenously into naive syngeneic BALB/c recipients. Two days
later recipients were treated with 5 3 105 BM-DC from BALB/c
mice that had been pulsed with OVA or were left unpulsed, and
that were either pretreated with IL-10 or left untreated. Eight days
later lymph node cells from all groups of recipients were prepared
and restimulated with the immunogenic peptide in vitro. The
number of OVA-TCR transgenic CD4+ T cells was determined by
FACS and equal amounts were used for restimulation. Proliferation
was measured by thymidine incorporation. As shown in Fig 4,
lymph node cells from recipients treated with DC-OVA showed a
strong proliferation upon stimulation with OVA peptide in vitro
whereas lymph node cells from recipients treated with DC-OVA-
IL-10 displayed 70% lower proliferation. In fact, proliferation of
lymph node cells derived from DC-OVA-IL-10 injected mice was
even lower than the proliferation of naive CD4+ transgenic T cells
(from untreated mice) that ®rst encountered antigen presentation
in vitro (Fig 4). To analyze whether the inhibitory effects persist
after restimulation with antigen, CD4+ T cells were isolated from
mice injected with DC-OVA and DC-OVA-IL-10, respectively,
and restimulated with OVA-pulsed epidermal cells. After 3 d the
Figure 2. IL-10 DC prevent induction of OVA-speci®c immune
responses. CD4+ T cells from naive DO11.10 mice were transferred to
syngeneic BALB/c mice. Two days later recipients were treated with
either IL-10-treated or untreated, OVA-pulsed or unpulsed DC as
described. Eight days later mice were immunized with OVA323±339 in
IFA subcutaneously and lymph node cells were prepared 10 d later.
Proliferation was induced by addition of OVA323±339 peptide to the
cultures and thymidine incorporation was determined after 3 d. Results
shown are representative of ®ve experiments with ®ve mice per group.
Groups are mice receiving naive CD4+ T cells and unpulsed DC (naive
T cells/DC), mice receiving naive CD4+ T cells and DC-OVA (naive T
cells/DC-OVA), mice receiving naive CD4+ T cells and DC-OVA-IL10
(naive T cells/DC-OVA-IL10), mice receiving naive CD4+ T cells and
DC-IL10 (naive T cells/DC-IL10) and mice receiving naive CD4+ T
cells and OVA peptide in IFA intraperitoneally (OVA-IFA i.p. =
tolerance control). Error bars represent SEM. *p < 0.05 versus DC
control. Statistical signi®cance was determined by t test.
Figure 3. OVA-pulsed IL-10-treated DC induce antigen-speci®c
tolerance in naive T cells in vivo. CD4+ T cells from naive DO11.10
mice were transferred to syngeneic BALB/c mice. Two days later
recipients were treated with either IL-10-treated or untreated, OVA-
pulsed as described. Eight days later mice were immunized with
OVA323±339 in IFA subcutaneously and CD4+ T cells were isolated from
lymph node and spleen cells 10 d later. CD4+ T cells were restimulated
in vitro with OVA-pulsed epidermal cells. After a rest period and addition
of IL-2 to cultures (2 U per ml) CD4+ T cells were restimulated with
OVA-pulsed epidermal cells and thymidine incorporation was
determined after 3 d. Results shown are representative of ®ve
experiments with ®ve mice per group. Groups are mice receiving naive
CD4+ T cells and DC-OVA and mice receiving naive CD4+ T cells and
DC-OVA-IL10. Error bars represent SEM.
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medium was supplemented with 2 U per ml IL-2. After a rest
period of 8 d equal numbers of OVA-TCR transgenic CD4+ T
cells were restimulated with OVA-pulsed epidermal cells. CD4+ T
cells from mice injected with DC-OVA-IL-10 after reconstitution
with sensitized CD4+ DO11.10 T cells remained impaired in their
capacity to proliferate (Fig 5). CD4+ T cells of mice injected with
DC or DC-IL-10 were driven into cell death by ex vivo
restimulation. In summary these data indicate not only that IL-
10-treated DC are able to suppress the function of preactivated
CD4+ transgenic T cells but that these effects persist after repeated
antigen restimulation.
DTH responses to OVA are suppressed in mice injected
with IL-10-treated, OVA-pulsed DC To look for an in vivo
correlate of our in vitro ®ndings, we performed classical DTH
experiments with OVA peptide in IFA. Animals that had been
either prophylactically or therapeutically treated as outlined above
or mice that had been control-treated were injected intradermally
with the immunogenic OVA peptide in IFA. Contralateral limbs
just received IFA to determine background swelling responses.
Forty-eight hours later footpad swelling reactions were measured.
In mice that had been prophylactically treated with DC-OVA-IL-
10, footpad swelling to OVA peptide was signi®cantly suppressed
compared to the control group of mice that had received DC or
DC-IL-10 (Fig 6). Omission of antigen in the in vivo treatment
resulted in swelling reactions similar to those observed in animals
reconstituted with naive T cells. Mice that had received DC-OVA
showed strong swelling responses. Similar results were obtained
when DTH reactions were performed in a therapeutic setting
(Fig 7). Analysis of DTH reactions in mice injected with DC-
OVA-IL-10 showed impaired immune responses after repeated
in vivo restimulation compared to mice injected with DC-OVA
(Fig 8). In lymphocyte and splenocyte populations of mice injected
with DC or DC-IL-10 no OVA-TCR transgenic T cells could be
detected after repeated antigen restimulation in vivo. This might
account for the small or absent swelling response seen in these
groups after antigen inocculation into the footpad (Fig 8).
Figure 5. OVA-pulsed IL-10-treated DC induce antigen-speci®c
tolerance in sensitized T cells in vivo. CD4+ T cells from DO11.10
mice that had been immunized with OVA peptide in IFA in vivo as
described were transferred to syngeneic BALB/c mice. Two days later
recipients were treated with either IL-10-treated or untreated, OVA-
pulsed or unpulsed DC as described. CD4+ T cells were isolated from
lymph node and spleen cells from recipients after 8 d and were
restimulated in vitro with OVA-pulsed epidermal cells. After a rest period
and addition of IL-2 to the cultures (2 U per ml) CD4+ T cells were
restimulated with OVA-pulsed epidermal cells and thymidine
incorporation was determined after 3 d. Results shown are representative
of ®ve experiments with ®ve mice per group. Groups are mice receiving
primed CD4+ T cells and DC-OVA and mice receiving primed CD4+
T cells and DC-OVA-IL10. Error bars represent SEM.
Figure 4. IL-10 DC downmodulate preexisting OVA-speci®c
immune responses in vivo. CD4+ T cells from DO11.10 mice that
had been immunized with OVA peptide in IFA in vivo as described were
transferred to syngeneic BALB/c mice. Two days later recipients were
treated with either IL-10-treated or untreated, OVA-pulsed as described.
Lymph node cells from recipients were prepared after 8 d. Proliferation
was induced by addition of OVA323±339 peptide to the cultures and
thymidine incorporation was determined after 3 d. Results shown are
representative of ®ve experiments with ®ve mice per group. Groups are
background proliferation of lymph nodes from naive transgenic animals
stimulated with OVA peptide in vitro (naive CD4+ T cells), mice
receiving primed CD4+ T cells and unpulsed DC (primed T cells/DC),
mice receiving primed CD4+ T cells and DC-OVA (primed T cells/
DC-OVA), mice receiving primed CD4+ T cells and DC-IL-10 (primed
T cells/DC-IL-10) and mice receiving primed CD4+ T cells and DC-
OVA-IL-10 (primed T cells/DC-OVA-IL-10). Error bars represent
SEM. *p < 0.05 and **p < 0.005 versus DC control. Statistical
signi®cance was determined by t test.
Figure 6. OVA-pulsed IL-10-treated DC prevent induction of
OVA-speci®c footpad swelling. CD4+ T cells from DO11.10 mice
were transferred to syngeneic BALB/c mice. Two days later recipients
were treated with either IL-10-treated or untreated, OVA-pulsed or
unpulsed DC as described. Eight days later mice were immunized with
OVA323±339 in IFA subcutaneously. Ten days later, mice were injected
into the footpad with 30 mg OVA323±339 in IFA intradermally, or just
IFA on the contralateral foot. Footpad swelling was determined 48 h
later and was calculated by deducting background swelling of IFA-
injected footpads from speci®c swelling reaction of the contralateral foot.
Results shown are representative of three sets of experiments with ®ve
mice per group. Groups are mice receiving OVA peptide intra-
peritoneally (i.p. peptide), mice receiving naive CD4+ T cells and DC-
OVA (naive T cells/DC-OVA), mice receiving naive CD4+ T cells and
DC-OVA-IL-10 (naive T cells/DC-OVA-IL-10), mice receiving naive
CD4+ T cells and DC-IL-10 (naive T cells/DC-IL-10), mice receiving
naive CD4+ T cells and unpulsed DC (naive T cells/DC), and mice
receiving only naive CD4+ T cells (naive T cells). Error bars indicate
SEM. *p < 0.05 versus DC control. Statistical signi®cance was
determined by t test.
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In summary, these data indicate that application of IL-10-treated
DC to OVA transgenic mice abrogates DTH reactions to OVA
in vivo.
DISCUSSION
IL-10 has been characterized as a modulator of APC function in
many different systems. It was shown that IL-10 downmodulates
the accessory functions of immature DC and monocytes, but not
B cells. The inhibitory effects of IL-10 were due to a down-
regulation of MHC class II molecules and costimulatory molecules
such as CD80, CD86, or ICAM-1 (de Waal et al, 1991; 1992a; Hsu
et al, 1992; Willems et al, 1994). The effects of IL-10 were distinct
for different subtypes of APC and also showed species dependency,
however (Enk et al, 1993; Steinbrink et al, 1997). Whereas the
expression of MHC class II molecules and costimulatory signals was
inhibited on both murine and human monocytes, various subtypes
of DC were differentially affected by IL-10. Human-blood-derived
DC showed reduced expression of MHC class II and CD80/CD86,
whereas no such markers were affected on murine Langerhans cells
(Enk et al, 1993; Steinbrink et al, 1997). In general mature DC were
resistant to IL-10 (Steinbrink et al, 1997).
Studies with murine Langerhans cells and human-blood-derived
DC have shown that pretreatment with IL-10 converts the
accessory functions from the induction of proliferation to anergy
induction. This was demonstrated for CD4+ and CD8+ T cells
(Steinbrink et al, 1997). In this study we analyzed the effect of IL-10
treatment on the expression of MHC class II and costimulatory
molecules on murine BM-DC and established a system to verify the
in vitro results in vivo. We demonstrated in an ex vivo transfer system
using CD4+ T cells from OVA-TCR transgenic mice in syngeneic
BALB/c recipients that IL-10-treated DC are able to prevent the
induction of sensitization in transgenic CD4+ T cells. Following
sensitization with immunogenic peptide in IFA, lymph node cells
from recipients treated with IL-10-treated, OVA-pulsed DC
showed a proliferation similar to that of a tolerance control group
that just received the immunogenic peptide in IFA intraperitone-
ally. In contrast, lymph node cells from recipients treated with
normal OVA-pulsed DC mounted a strong proliferative response
upon stimulation of the cells with immunogenic peptide in vitro.
More importantly, IL-10-treated DC were also able to suppress
ongoing immune responses in presensitized T cells. For this,
CD4+ T cells from in vivo sensitized transgenic animals were
tranferred into syngeneic recipients. When recipients were injected
with IL-10-treated OVA-pulsed DC, lymph node T cells that were
prepared and restimulated with immunogenic peptide in vitro
showed a signi®cantly lower T cell proliferation compared with the
control group. Even after repeated antigen restimulation in vivo and
in vitro full proliferative capacity of DC-OVA-IL10-treated cells
cannot be restored.
Our results are in agreement with earlier work by Groux et al
(1996). Besides describing a direct tolerizing effect of IL-10 on
CD4+ T cells in their earlier work, these authors have recently
developed a transgenic mouse system where the effect is achieved
by the expression of human IL-10 under the control of the murine
MHC class II Ea promoter (Groux et al, 1999). In these animals, IL-
10 is secreted by APC such as macrophages or DC. Although no
gross abnormalities in serum Ig levels or peripheral lymphocyte
populations were detectable in these mice, transgenic animals failed
to mount detectable T or B cell immune responses to OVA. In
addition, these animals were highly susceptible to infection with
intracellular pathogens like Listeria monocytogenes or Leishmania
major. Although the exact reason for the poor immune response in
IL-10 transgenic mice remained undetermined, T cell anergy and
the induction of regulatory (Tr1-type) T cells were discussed as
possible mechanisms.
In human disease, there is also ample evidence to support our
®ndings that IL-10 inhibits DC function in vivo. Mitra et al (1995)
have shown that the secretion of IL-10 in human psoriatic plaques
inhibits the APC function of human dermal DC. The effect was
mediated by an inhibition of the expression of costimulatory
molecules such as CD86, CD80, as well as HLA-DR molecules.
For patients with malignant melanoma it has been demonstrated
Figure 8. IL-10-treated DC inhibit footpad swelling after antigen
restimulation in vivo. CD4+ T cells from DO11.10 mice that had been
immunized with OVA peptide in IFA in vivo as described were
transferred to syngeneic BALB/c mice. Two days later recipients were
treated with either IL-10-treated or untreated, OVA-pulsed or unpulsed
DC as described. Mice were injected with OVA323±339 in IFA
subcutaneously after 8 d. Ten days later mice were injected into the
footpad with 30 mg OVA323±339 in IFA intradermally, or just IFA on the
contralateral foot. Footpad swelling was determined 48 h later. Results
shown are representative of ®ve experiments with ®ve mice per group.
Groups are mice receiving unpulsed DC, mice receiving DC-IL10, mice
receiving DC-OVA, and mice receiving DC-OVA-IL10.
Figure 7. OVA-pulsed IL-10 DC downmodulate OVA-speci®c
footpad swelling in mice injected with presensitized T cells in vivo.
CD4+ T cells from DO11.10 mice that had been immunized with OVA
peptide in vivo as described were transferred to syngeneic BALB/c mice.
Two days later recipients were treated with either IL-10-treated or
untreated, OVA-pulsed or unpulsed DC as described. Eight days later,
mice were injected into the footpad with 30 mg OVA323±339 in IFA
intradermally, or just IFA on the contralateral foot. Footpad swelling was
determined 48 h later. Results shown are representative of three sets of
experiments with ®ve mice per group. Groups are mice receiving
primed CD4+ T cells and DC-OVA (primed T cells/DC-OVA), mice
receiving primed CD4+ T cells and DC-OVA-IL10 (primed T cells/
DC-OVA-IL10), mice receiving primed CD4+ T cells and DC-IL10
(primed T cells/DC-IL10), mice receiving primed CD4+ T cells and
unpulsed DC (primed T cells/DC), and mice receiving just primed
CD4+ T cells (primed T cells). Error bars indicate SEM. *p < 0.05 versus
DC control. Statistical signi®cance was determined by t test.
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that high amounts of IL-10 in patients' sera is associated with a poor
prognosis (Dummer et al, 1995). Also, secretion of IL-10 by
melanoma cells was shown to convert local DC function from
induction of tumor immunity to the induction of T cell anergy
(Dummer et al, 1996). Similar results were obtained for lung
cancer, where T-cell-derived IL-10 suppressed both APC and T
cell functions (Smith et al, 1994).
On the other hand, the inhibitory effect of IL-10-treated DC
in vivo makes these cells an attractive tool for future studies in
experimental murine and hopefully human autoimmune diseases.
The exact nature of the immune-modulatory effect exerted by IL-
10-treated DC still needs to be analyzed (e.g., suppression versus
anergy induction). Nevertheless there is a clear difference between
OVA-pulsed IL-10-treated DC and control DC. In mice injected
with control DC (DC or DC-IL10) no OVA-TCR transgenic T
cells can be detected after repeated restimulation with OVA peptide
in vivo, whereas CD4+ transgenic T cells can be isolated following
antigen restimulation in mice injected with OVA-pulsed IL-10-
treated DC. In addition, CD4+ T cells of mice injected with
control DC were driven into cell death by secondary stimulation
in vitro. Thus OVA-pulsed IL-10-treated DC seem to induce T cell
survival without T cell activation. The inhibitory effect of DC-
IL10 most likely is not a direct effect of IL-10 on CD4+ T cells, as
no IL-10 was released by IL-10-treated DC (not shown). Studies to
better de®ne the nature of the tolerizing T cell response induced by
IL-10-treated APC and the molecules involved in this reaction are
currently in progress in our laboratory.
Supported by Deutsche Forschungsgemeinschaft SFB 548-A3.
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